Clinical Trial Update: Dose EScalation Induction of EvERolimus [Phase 2]

View source ↗

Summary

Phase 2 dose-escalation trial of EvERolimus in hormone receptor–positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | Status: COMPLETED